Rates of CLABSI and MBI-LCBI in a hematology-oncology unit at an academic hospital started climbing in April 2016. A comprehensive multidisciplinary approach was implemented to mitigate the risk. These were the results in the decline of the rates of both CLABSI and MBI-LCBI” Riley et al (2018).

Background:

Bloodstream infection, including central line-associated bloodstream infection (CLABSIs) and mucosal barrier injury laboratory-confirmed bloodstream infections (MBI-LCBIs), is a severe, life-threatening infectious complication in immunocompromised patients. Rates of CLABSI and MBI-LCBI in a hematology-oncology unit at an academic hospital started climbing in April 2016. A comprehensive multidisciplinary approach was implemented to mitigate the risk. These were the results in the decline of the rates of both CLABSI and MBI-LCBI.

Reference:
